BeStock  

Takeda Pharmaceutical TAK

US equityMarket cap rank #310Infectious Disease
$21.77 +$0.36 (+1.68%)
Market closed · Nov 21, 9:10 am ET · Last extended-hours $22.09 +1.47%
Open$21.82
Prev close$21.41
Day range$21.74 – $22.07
Volume3.80M
Market cap$69.76B
P/E (TTM)311.0
Dividend yield1.44%

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

TAK at a glance

TAK is priced at $21.77 right now, up 1.68% on the session. That puts its market value at $69.76B, 310th largest among the 3753 stocks we cover.

The 52-week range is $13.92 to $22.07. Today's price is about 96% of the way from the low to the high. Holders are ahead 54.9% over twelve months, and up 19.4% across the last three months.

On the chart it holds above both the 50-day ($19.72) and 200-day ($17.82) moving averages; RSI is 69, and the last 30 sessions moved at roughly 22% annualized volatility.

In the quarter ended Sep 2026 the company brought in ¥1.19T of revenue, up 6.7% from a year earlier, with ¥192.46B of net profit (a 0.9% margin).

Buyers are paying 311.0 times trailing earnings, 677% above its five-year average of 40.0. The median for its industry group is 35.3.

1 analysts follow the stock and the average call is "buy". The mean target, $50.46, sits 131.8% over where the stock trades.

This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.

Takeda Pharmaceutical: the business

Takeda is a Japanese drugmaker with products in gastrointestinal, rare disease, neuroscience and oncology, and plasma-derived therapies.

What tends to move it. Patent expiry of Vyvanse and growth of newer products are the central issues.

Where the case gets weaker. Vyvanse's loss of patent protection removes a well-established revenue source, and if the newer products meant to replace it grow more slowly than planned, the gap would show up directly in earnings with limited room to make it up elsewhere in the near term.

Written by hand by the BeStock desk and revised when a business changes. how we work. Spot something out of date? Tell us.

Key statistics

Bid / Ask$18.80 / $22.04
Average price today$21.87
Volume3.80MAvg (90d) 3.03M
Turnover$83.19M
Turnover rate0.12%of shares outstanding
Volume ratio0.98vs. recent average pace
Day amplitude1.52%
Market cap$69.76B
Float market cap$67.54B
Shares outstanding3.10B
EPS (TTM)-$0.30
P/E (TTM)311.00
P/B1.50
Book value / share$14.49
Earnings yield0.32%
Dividend (TTM)$0.31 / shareYield 1.44%
Net profit (TTM)-$970.94M
Net assets$46.44B
30-day volatility21.8%annualized
Avg daily range (ATR)1.96%of price, 14 days
Max drawdown (1y)-19.9%0.0% from 1y peak

Quote as of Nov 21, 2026 9:10 am ET. Prices can lag the live tape. This is background information, not a recommendation.

BeStock Grade

C
BeStock Grade

Composite of 4 factors below, ranked against the 3734 U.S. stocks BeStock covers.

F
Valuation

Cheaper than usual on its own 5-year P/E history scores higher.

D
Income

Higher trailing yield than most of BeStock’s coverage scores higher.

A
Momentum

Trading closer to its 52-week high than most peers scores higher.

B
Wall Street

1 analysts, consensus Buy.

How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.

Six-factor research snapshot

Overall percentile: 24.5 · 2026-11-22 14:27 UTC. Higher values indicate a stronger relative ranking.

FactorPercentile
Valuation4.7
Growth37.1
Profitability36.5
Momentum99.1
Financial health38.5
Analyst view—

Price forecast

What Wall Street analysts and Morningstar's fair-value model expect for the stock

Analyst price target (avg)$50.46+131.8% vs. current price
Consensus ratingBuy1 analysts covering
Morningstar fair value$21.02Close to fair value

Wall Street’s average 12-month target is $50.46, 131.8% above today’s price, with a consensus rating of Buy. Morningstar’s fair value model puts the stock at $21.02, so shares trade 3.6% above that estimate. On earnings multiple, it sits in the 100th percentile of its own five-year valuation range (pricier than usual).

Figures are Wall Street analyst consensus and Morningstar’s independent fair-value model, sourced as noted above.

Performance

Price return over each window, from adjusted daily and weekly closes

1 day
+1.7%
1 week
+1.6%
1 month
+6.9%
3 months
+19.4%
6 months
+34.0%
Year to date
+42.0%
1 year
+54.9%
3 years
+55.8%
Day range
$21.74$22.07
52-week range
$13.92$22.07

Technical signals

Full technicals →
Trend readStrong uptrend

6 bullish · 1 bearish of 7 signals

IndicatorValueSignal
Price vs 20-day average+3.7%Bullish
Price vs 50-day average+10.4%Bullish
Price vs 200-day average+22.1%Bullish
50-day vs 200-day50d above 200dBullish
RSI (14)69.3Bullish
MACD (12,26,9)0.54Bearish
Bollinger band position90%Bullish

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

How TAK ranks on BeStock

Market value#309 of 3734
P/E (cheapest = 1)#2886 of 2917
Dividend yield#1569 of 2245
Closeness to 52-week high#42 of 3724
Dollar volume today#1095 of 3734

Ranks are among the 3,734 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.

Set against the peer table: at 311.0x earnings, TAK looks expensive against the market, and trades 781% above the 35.3x median among Infectious Disease names. The two comparisons do not always agree.

TAK is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.

Since 2020-12-28, the strategy has returned 401.7% (183.6% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated daily — not a guarantee of future results, and not a BeStock recommendation.

Strategy Backtest

Pick a strategy above and run the backtest to see its simulated performance on TAK.

Rule-based technical strategies computed from this stock’s own price history only. Signals use only data available through the prior trading day (no look-ahead), and trading costs, slippage and taxes aren’t modeled. A backtested rule performing well in the past is not a guarantee of future results — this is an educational illustration, not investment advice.

Community Sentiment on TAK

No votes yet — be the first to weigh in.

Reader sentiment, not investment advice. One vote per visitor; click again to change it.

TAK stock: common questions

How is Takeda Pharmaceutical stock doing today?

$21.77 is the latest print for TAK, a move of +1.68% against yesterday's close of $21.41. Today's low and high so far: $21.74 and $22.07.

What is TAK worth in total?

Equity value comes to $69.76B at the current price. By that measure it is number 310 of the 3753 names in our coverage.

What multiple of earnings does TAK sell for?

Buyers pay 311.0 times the last twelve months of profit (EPS $-0.30). Averaged over five years the multiple has been 40.0, and today's level ranks in the 100th percentile of its own history.

Where does TAK sit in its 52-week range?

The year's floor is $13.92 and the ceiling $22.07. Shares are 1.3% away from that ceiling.

Does TAK send cash back through a dividend?

It does. Payouts over the past twelve months work out to a 1.44% yield; the latest ex-dividend date was March 31, 2026.

Do Wall Street analysts like TAK?

Of 1 analysts, 100% say buy, 0% hold and 0% sell. Price targets average $50.46, with the most cautious at $50.46 and the most optimistic at $50.46.

How does Takeda Pharmaceutical make money?

Takeda is a Japanese drugmaker with products in gastrointestinal, rare disease, neuroscience and oncology, and plasma-derived therapies.

BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.

Discussion

No comments yet — be the first to weigh in on TAK.

Sign in to join the discussion.

Scroll to Top